Nephrogenic systemic fibrosis: A gadolinium-associated fibrosing disorder in patients with renal dysfunction

Annals of the Rheumatic Diseases

Volumn 67, Issue SUPPL. 3, 2008, Pages

  Kay, Jonathan ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; COLLAGEN TYPE 1; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOSPORIN A; FIBRONECTIN; GADOLINIUM; GADOLINIUM PENTETATE; IMATINIB; PENTOXIFYLLINE; PREDNISONE; PROTEIN TYROSINE KINASE; RANITIDINE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EXPOSURE; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSIS; HEMODIALYSIS; HUMAN; HYPERPIGMENTATION; JOINT CONTRACTURE; KIDNEY DISEASE; KIDNEY FUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SKIN BIOPSY; SKIN EXAMINATION; SKIN FIBROBLAST; SKIN FIBROSIS;

CONTRAST MEDIA; DRUG ERUPTIONS; GADOLINIUM; HUMANS; HYPERPIGMENTATION; NEPHROGENIC FIBROSING DERMOPATHY; RENAL INSUFFICIENCY, CHRONIC;

EID: 56749104546     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.102475     Document Type: Conference Paper

References (35)

1. Centers for Disease Control and Prevention. Fibrosing skin condition among patients with renal disease - United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 2002;51:25-6.
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
3. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-93.
4. Edsall LC, English JC 3rd, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004;31:247-53.
5. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204.
6. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114:563-72.
7. Levine JM, Taylor RA, Elman LB, Bird SJ, Lavi E, Stolzenberg ED, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569-77.
8. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008;358:827-38.
9. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903- 6.
10. 1 expression in affected skin. Arthritis Rheum 2004;50:2660-6.
11. Saenz A, Mandal R, Kradin R, Hedley-Whyte ET. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006;449:389-91.
12. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130:209-12.
13. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005;46:754-9.
14. Cassis TB, Jackson JM, Sonnier GB, Callen JP. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 2006;45:56-9.
15. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56:3433-41.
16. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-4.
17. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
18. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
19. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-6.
20. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
21. Boyd AS, Sanyal S, Abraham JL. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. J Am Acad Dermatol 2008;59:356-8.
22. Anavekar NS, Chong AH, Norris R, Dowling J, Goodman D. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient. Australas J Dermatol 2008;49:44-7.
23. Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 2007;3:111-5.
24. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425-32.
25. Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-76.
26. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007;357:720-2.
27. Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88.
28. Kay J, Kagan A, Chibnik LB, High WA, Nazahan RM, Abujudeh HH. Nephrogenic fibrosing dermopathy develops following gadopentetate dimeglumine exposure. [Abstract]. Arthritis Rheum 2007;56(9 Suppl):S546-7.
29. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol 2008;5:45-52.
30. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001;42:339- 41.
31. Baron PW, Cantos K, Hillebrand DJ, Hu KQ, Ojogho ON, Nehlsen-Cannarella S, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003;25:204-9.
32. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004;351:2219-27.
33. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007;143:1025-30.
34. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008;58:2543-8.
35. Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.